Relaxes vascular smooth muscle, activates guanylate cyclase by releasing nitric oxide (NO), increases cyclic guanosine monophosphate (cGMP) in smooth muscle cells, thereby relaxing vascular smooth muscle, dilating peripheral arteries and veins, reducing myocardial oxygen consumption and increasing oxygen supply.

Potassium is the main cation in cells and is involved in the regulation of acid-base balance, the synthesis of sugar and protein, and the conversion of adenosine diphosphate into triphosphate. It is involved in the excitation process between nerves and their innervated organs, between neurons, and in the formation of neurotransmitters (acetylcholine) at nerve endings. It affects cardiac activity and can cause arrhythmias when potassium is low. It is an ion necessary to maintain normal skeletal muscle tension and its deficiency will result in muscle weakness and convulsions.

This product is a nucleoside derivative, which promotes brain metabolism and improves brain circulation by reducing cerebrovascular resistance and increasing cerebral blood flow. In addition, it can enhance the function of the ascending activation system of the brainstem reticular structure, enhance the function of the pyramidal system, and improve motor paralysis, so it has a certain effect on promoting the recovery of brain function and promoting awakening.

This product is an anti-deoxyribonucleic acid (DNA) virus drug. Its pharmacological action is to bind to the viral deoxyribonucleic acid polymerase, reduce its activity and inhibit DNA synthesis. After entering the cell, adenosine monophosphate is phosphorylated to generate adenosine diphosphate (Ara-ADP) and adenosine triphosphate (Ara-ATP). The antiviral activity is mainly caused by adenosine triphosphate (Ara-ATP). Ara-ATP and deoxyadenosine triphosphate (dATP) compete to bind to viral DNAP, thereby inhibiting the activity of the enzyme and the synthesis of viral DNA. At the same time, it inhibits the activity of viral nucleotide reductase and inhibits the synthesis of viral DNA. It can also inhibit the activity of viral DNA terminal deoxynucleotidyl transferase, so that Ara-A penetrates into the viral DNA and connects to the end of the DNA chain 3prime;-OH position, inhibiting the continued synthesis of viral DNA.

This product is an anti-deoxyribonucleic acid (DNA) virus drug. Its pharmacological action is to bind to the viral deoxyribonucleic acid polymerase, reduce its activity and inhibit DNA synthesis. After entering the cell, adenosine monophosphate is phosphorylated to generate adenosine diphosphate (Ara-ADP) and adenosine triphosphate (Ara-ATP). The antiviral activity is mainly caused by adenosine triphosphate (Ara-ATP). Ara-ATP and deoxyadenosine triphosphate (dATP) compete to bind to viral DNAP, thereby inhibiting the activity of the enzyme and the synthesis of viral DNA. At the same time, it inhibits the activity of viral nucleotide reductase and inhibits the synthesis of viral DNA. It can also inhibit the activity of viral DNA terminal deoxynucleotidyl transferase, so that Ara-A penetrates into the viral DNA and connects to the end of the DNA chain 3prime;-OH position, inhibiting the continued synthesis of viral DNA.